76986-15-7

Usage

General Description

2-amino-2-(4-methoxyphenyl)acetamide, also known as memantine, is a medication used to treat moderate to severe Alzheimer's disease. It works by blocking the action of a neurotransmitter in the brain called glutamate, which is believed to be involved in the development and progression of Alzheimer's disease. Memantine is also used to treat dementia associated with Parkinson's disease and to reduce some of the symptoms of dementia, such as confusion and agitation. It is generally well-tolerated, with common side effects including dizziness, headache, and constipation. It is available in both oral and injectable formulations and is typically prescribed as part of a comprehensive treatment plan for Alzheimer's disease and other forms of dementia.

Upstream product

• 13226-99-8 amino(3-chloro-4-methoxyphenyl)acetic acid methyl ester hydrochloride 
• 2540-53-6 2-(4-methoxyphenyl)glycine 
• 74273-47-5 methyl 2-amino-2-(4-methoxyphenyl)acetate 
• 33646-40-1 4-methoxymandelonitrile 
• 67-56-1 methanol 

Downstream Products

• 1108685-94-4 L-2-(2-methoxy-acetylamino)-2-(4-methoxyphenyl)-acetamide 
• 931313-78-9 tert-butyl 2-(4-methoxyphenyl)-3-oxo-1,4,8-triazaspiro[4.5]dec-1-ene-8-carboxylate 
• 6617-78-3 5-(4-methoxyphenyl)imidazolidone-2,4-dione 
• 24593-48-4 (2S)-2-amino-2-(4-methoxyphenyl)acetic acid 
• 24593-49-5 D-(-)-2-(4-methoxyphenyl)glycine 
• 67412-96-8 D-(-)-4-methoxyphenylglycine amide 
• 96155-89-4 L-p-methoxyphenylglycine amide 
• 25084-42-8 C₉H₁₀Cl₂N₂O₂ 

Relevant academic research and scientific papers

EGFR DIMER DISRUPTORS AND USE OF THE SAME

Provided herein are compounds that modulate EGFR and methods of using the same, for example to treat cancer.

2-ARYL GLYCINAMIDE DERIVATIVES

The disclosure provides compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their uses in inhibiting β-amyloid peptide ( β-AP) production.

Glyt1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders

The invention provides a compound of formula (I) or a solvate thereof: wherein R1, R2, R3, R4, R5, R6, and n are as defined in the specification, and uses of such compounds. The compounds i

N-PHENYL-2-0X0-1,4-DIAZASPIR0 [4.5] DEC-3-EN-1-YL ACETAMIDE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER INHIBITORS

Compounds of formula (I) and salts and solvates are provided: Formula (I) Uses of the compounds as medicaments, and in the manufacture of medicament for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention d

COMPOUNDS WHICH INHIBIT THE GLYCINE TRANSPORTER AND USES THEREOF

Compounds of formula (I) and salts and solvates thereof are provided: wherein R1 to R8 and n are defined in the description. Uses of the compounds as medicaments, and in the manufacture of medicament for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder are also disclosed. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.

1-(2-ARYL-2-OXOETHYL)-3-PHENYL-1, 4-DIAZASPIRO [4.5]DEC-3-EN-2-ONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER INHIBITORS

Novel acetophenone compounds of formula (I), compositions containing (I), processes for the preparation of (I), and use of (I) as inhibitors of the glycine transporter, are provided. Definitions of Ar, R5, R6, R7, R8

Therapeutic L- and DL- phenylglycines to treat diseases or disorders of reduced blood flow or oxygen availability

L- and DL- Phenylglycines of the formula STR1 and pharmaceutically acceptable salts thereof, wherein R is hydrogen or methyl and R1 is NH2, OH or completes a carboxylic ester group, useful in treating certain cardiovascular diseases, diabetes and obesity.